Physician profile
Cindy Delee
NPI 1144774688
$3,097.58
in general payments reported to CMS, 2019-2025
13 companies · $629 in 2025
The $629 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $25.40 · 2022: $14.51 · 2023: $1,967 · 2024: $354 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Travel and Lodging: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.43 |
| Travel and Lodging | $1,447.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,737.83 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $308.67 | 2023-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $295.49 | 2022-2025 | Rocklatan, Tryptyr, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $117.49 | 2023-2025 | Cequa |
| Thea Pharma INC. | $113.14 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.83 | 2019 | |
| Abbvie INC. | $96.30 | 2023-2025 | Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $95.07 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $82.20 | 2023-2024 | Acuvue |
| Oyster Point Pharma, INC. | $78.51 | 2024-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $25.40 | 2020 | |
| Dompe US, INC. | $20.51 | 2025 | Oxervate |
| Harrow Eye, LLC | $19.14 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Delee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.